ARIA-E – Talk Bio

Prothena’s Alzheimer’s Trial Hit by High ARIA-E Rates, Resulting in ‘Non-Competitive’ Profile

2 weeks ago talkbio0Tagged Alzheimer 's disease, amyloid beta antibody, ARIA-E, ASCENT, Cerebral Edema, clinical program, non-competitive profile, Prothena, PRX012, subcutaneous administration

Prothena; PRX012; Alzheimer’s disease; ARIA-E; brain swelling; phase 1 trial; non-competitive profile; amyloid beta antibody; ASCENT clinical program; subcutaneous administration

Eli Lilly’s Kisunla Shows Reduced Brain Swelling with Modified Dosing Regimen in Alzheimer’s Patients

11 months ago talkbio0Tagged Alzheimer 's disease, ARIA-E, Cerebral Edema, Changing, dosing, Eli, Eli Lilly, Kisunla, Risk, Treatment Protocols

Eli Lilly, Kisunla, Alzheimer’s disease, brain swelling, modified dosing regimen, ARIA-E risk reduction

Modified Dosing Regimen of Eli Lilly’s Alzheimer’s Drug Kisunla (Donanemab) Reduces Brain Swelling

11 months ago talkbio0Tagged Alzheimer 's disease, amyloid-related imaging abnormalities, ARIA-E, Cerebral Edema, Changing, Donanemab, dosing, Eli, Eli Lilly, Kisunla, oedema/effusion, TRAILBLAZER-ALZ, Treatment Protocols, Trial Phase 3B

Alzheimer’s disease, Eli Lilly, Kisunla (donanemab), Modified dosing regimen, ARIA-E (amyloid-related imaging abnormalities with oedema/effusion), Brain swelling, TRAILBLAZER-ALZ 6 Phase IIIb trial